Loading...
Loading...
Browse all stories on DeepNewz
VisitWhich field will see the first major breakthrough using AlphaFold2 by end of 2025?
Drug Discovery • 25%
Genetic Research • 25%
Agricultural Improvement • 25%
Other • 25%
Scientific publications and press releases highlighting breakthroughs
David Baker, Demis Hassabis, and John Jumper Win 2024 Nobel Prize in Chemistry for Protein Research with AlphaFold2
Oct 9, 2024, 10:29 AM
The 2024 Nobel Prize in Chemistry has been awarded to David Baker, Demis Hassabis, and John Jumper for their groundbreaking work in protein research. David Baker was recognized for his contributions to computational protein design, while Demis Hassabis and John Jumper were honored for their advancements in protein structure prediction using artificial intelligence. The Royal Swedish Academy of Sciences announced that Hassabis and Jumper's AI model, AlphaFold2, has significantly accelerated the process of predicting protein structures, which previously took years but now takes just minutes. This achievement has profound implications for the fields of biology and medicine, potentially revolutionizing drug discovery and other applications.
View original story
Pharmaceuticals • 25%
Biotechnology • 25%
Genomics • 25%
Other • 25%
Drug Discovery • 25%
Agriculture • 25%
Climate Science • 25%
Other • 25%
Cancer treatment development • 25%
Antibiotic resistance solutions • 25%
Neurodegenerative disease therapy • 25%
Other • 25%
Protein Structure Elucidation • 25%
Drug Discovery • 25%
Genomic Research • 25%
Other • 25%
Drug Discovery • 25%
Agricultural Biotechnology • 25%
Personalized Medicine • 25%
Other • 25%
Drug Discovery • 25%
Genomics • 25%
Structural Biology • 25%
Other • 25%
Drug Discovery • 25%
Genomic Research • 25%
Structural Biology • 25%
Other • 25%
Cancer treatment • 25%
Infectious diseases • 25%
Neurological disorders • 25%
Other • 25%
Cancer treatment • 25%
Neurodegenerative disease treatment • 25%
Infectious disease treatment • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Other • 25%
Novartis • 25%
Roche • 25%